HomeCompareERYP vs EPRT

ERYP vs EPRT: Dividend Comparison 2026

ERYP yields 256.41% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERYP wins by $541.16M in total portfolio value
10 years
ERYP
ERYP
● Live price
256.41%
Share price
$0.78
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$541.22M
Annual income
$306,262,465.48
Full ERYP calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ERYP vs EPRT

📍 ERYP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERYPEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERYP + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERYP pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERYP
Annual income on $10K today (after 15% tax)
$21,794.87/yr
After 10yr DRIP, annual income (after tax)
$260,323,095.66/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ERYP beats the other by $260,312,181.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERYP + EPRT for your $10,000?

ERYP: 50%EPRT: 50%
100% EPRT50/50100% ERYP
Portfolio after 10yr
$270.64M
Annual income
$153,137,653.10/yr
Blended yield
56.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ERYP
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERYP buys
0
EPRT buys
0
No recent congressional trades found for ERYP or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERYPEPRT
Forward yield256.41%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$541.22M$63.4K
Annual income after 10y$306,262,465.48$12,840.73
Total dividends collected$516.37M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ERYP vs EPRT ($10,000, DRIP)

YearERYP PortfolioERYP Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$36,341$25,641.03$11,205$505.18+$25.1KERYP
2$125,971$87,086.09$12,672$682.46+$113.3KERYP
3$416,912$282,122.92$14,490$930.48+$402.4KERYP
4$1,318,722$872,626.36$16,786$1,282.69+$1.30MERYP
5$3,990,640$2,579,607.07$19,753$1,791.56+$3.97MERYP
6$11,565,551$7,295,566.53$23,677$2,541.64+$11.54MERYP
7$32,135,691$19,760,551.21$29,008$3,672.99+$32.11MERYP
8$85,699,274$51,314,084.97$36,463$5,425.08+$85.66MERYP
9$219,589,910$127,891,686.63$47,238$8,221.57+$219.54MERYP
10$541,223,669$306,262,465.48$63,385$12,840.73+$541.16MERYP

ERYP vs EPRT: Complete Analysis 2026

ERYPStock

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Full ERYP Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ERYP vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERYP vs SCHDERYP vs JEPIERYP vs OERYP vs KOERYP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.